Peptide education
Leuprolide
Leuprorelin · Leuprolide acetate · Lupron Depot · Lupron Depot-Ped · Eligard
Leuprolide is a prescription medicine that changes the signals between the brain and the ovaries or testes. It first stimulates the GnRH receptor, then sustained treatment suppresses the signals that drive sex-hormone production. Different leuprolide products are used for advanced prostate cancer, endometriosis, certain fibroid-related anemia, and early puberty.
Leuprolide has established medical uses, but a possible initial hormone rise, prolonged hormone suppression, and product-specific warnings make the exact formulation and diagnosis important.
Overview
Quick answer
Lupron Depot, Lupron Depot-Ped, and Eligard have different labeled indications, routes, strengths, and release periods. Dosage and timing depend on the specific product.
What is it prescribed for?
US product labels cover advanced prostate cancer, endometriosis, preoperative improvement of anemia caused by fibroids in a defined setting, and central precocious puberty. The indication belongs to the specific product, not every leuprolide formulation.
Why does an agonist suppress hormones?
The first effect is stimulation. With continued exposure, the pituitary response is suppressed, reducing LH and FSH and the sex hormones they normally help regulate.
Can leuprolide cause an initial hormone rise?
Yes. Testosterone can rise initially with the prostate-cancer depot, and symptoms can temporarily worsen. The pediatric label also describes a possible early rise in hormones and transient pubertal signs.
Are the depot injections interchangeable?
No. Lupron Depot is given intramuscularly; Eligard is a subcutaneous depot. The pediatric and gynecologic labels have their own strengths, indications, and dosing instructions.
Evidence
Evidence snapshot
In an open-label comparison, the estimated rate of sustained testosterone suppression was 96.4% with monthly leuprolide and 97.2% with the labeled degarelix study schedule. This was a hormone endpoint, not a survival comparison.
In a six-month study of 84 children, the estimated rate of peak-stimulated LH below 4 mIU/mL from months 2 through 6 was 78.4% with 11.25 mg and 95.2% with 30 mg. Assessments were at months 2, 3, and 6.
The 3.75 mg label covers endometriosis and a separate preoperative anemia indication with iron for selected patients with fibroids. Its treatment limits differ by indication.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| Leuprolide can suppress testosterone in advanced prostate cancer. | The prostate-cancer depot is indicated for advanced disease. A randomized comparison found sustained testosterone suppression with a monthly intramuscular leuprolide schedule. | Continued GnRH agonist exposure reduces pituitary gonadotropin secretion and downstream testosterone production. Testosterone can rise initially. | Supported for the labeled cancer setting, with attention to a possible initial flare and the patient's treatment plan. |
| Leuprolide treats endometriosis and fibroids in the same way. | The 3.75 mg label covers endometriosis management. Its fibroid indication is narrower: with iron, before surgery, to improve anemia in patients for whom three months of hormonal suppression is considered necessary. | Endometriosis management and preoperative treatment of fibroid-related anemia have different duration and add-back rules. | |
| Leuprolide treats central precocious puberty. | In a six-month study of 84 children, the estimated rate of peak-stimulated LH below 4 mIU/mL from months 2 through 6 was 78.4% with 11.25 mg and 95.2% with 30 mg. Assessments were at months 2, 3, and 6. | Lupron Depot-Ped is indicated for central precocious puberty. Its label calls for hormonal and clinical monitoring during treatment. |
Bottom line
Main takeaway
Leuprolide turns down sex-hormone signals, though hormone levels can rise at first. It is prescribed for specific prostate, gynecologic, and pediatric conditions.
Check the product name, indication, route, dose interval, and monitoring plan. An intramuscular depot and a subcutaneous depot are not interchangeable by dose alone.
The prostate cancer comparison measured testosterone suppression, while the pediatric trial measured stimulated LH suppression.
Identity
What it is
Leuprolide is a synthetic nine-amino-acid analog of GnRH. GnRH normally signals the pituitary to release luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH. Leuprolide's sustained exposure eventually reduces that signaling.
Its clinical use depends on which sex-hormone effect is being treated. The relevant US labels distinguish prostate cancer, gynecologic care, and pediatric central precocious puberty.
Use context
Routes, doses, and cycle patterns
Leuprolide schedules depend on the product and condition. Lupron Depot is given intramuscularly, Eligard is a subcutaneous depot, and Lupron Depot-Ped has its own pediatric strengths and monitoring schedule.
Human studies and product labels
Lupron Depot for advanced prostate cancer
- Purpose
- Treatment of advanced prostate cancer
- Context
- US product label
- Route
- Intramuscular injection by a healthcare provider
- Amount
- 7.5 mg, 22.5 mg, 30 mg, or 45 mg, depending on the formulation
- Frequency
- Respectively every 4, 12, 16, or 24 weeks
- Duration
- Determined in the clinical treatment plan
Each strength has its own release characteristics. The label warns against fractional doses or combining depot doses to substitute for another formulation.
Eligard for advanced prostate cancer
- Purpose
- Treatment of advanced prostate cancer
- Context
- US product label
- Route
- Subcutaneous injection
- Amount
- 7.5 mg, 22.5 mg, 30 mg, or 45 mg, depending on the formulation
- Frequency
- Respectively every 1, 3, 4, or 6 months
Eligard is a separate subcutaneous depot product. The same milligram number does not make it the same formulation as an intramuscular Lupron Depot product.
Lupron Depot 3.75 mg for endometriosis
- Purpose
- Endometriosis management
- Context
- US product label
- Route
- Intramuscular injection by a healthcare provider
- Amount
- 3.75 mg
- Frequency
- Once monthly
- Duration
- Initial treatment for up to six months; total treatment no more than 12 months
Initial treatment may be with or without norethindrone acetate add-back. If symptoms recur, the label permits up to six months of retreatment only with add-back and calls for bone-density assessment before retreatment.
Lupron Depot 3.75 mg for fibroid-related anemia
- Purpose
- Preoperative hematologic improvement with iron therapy
- Context
- US product label for a defined preoperative setting
- Route
- Intramuscular injection by a healthcare provider
- Amount
- 3.75 mg
- Frequency
- Once monthly
- Duration
- Up to three months
The label specifies use with iron before surgery and does not indicate this fibroid regimen with norethindrone add-back.
Three-month Lupron Depot-Ped
- Purpose
- Central precocious puberty
- Context
- US product label
- Route
- Intramuscular injection by a healthcare professional
- Amount
- 11.25 mg or 30 mg
- Frequency
- Every 12 weeks
The pediatric label includes other formulations and specifies hormonal and clinical monitoring. Dose and duration are individualized by the treating clinician.
Pediatric dose-ranging study
- Purpose
- Stimulated LH suppression in central precocious puberty
- Context
- Six-month randomized open-label study
- Route
- Intramuscular depot injection
- Amount
- 11.25 mg or 30 mg
- Frequency
- Every three months
- Duration
- Six months of study follow-up
Peak-stimulated LH below 4 mIU/mL from months 2 through 6 was estimated at 78.4% and 95.2% for the respective groups using a prespecified life-table analysis. Assessments were at months 2, 3, and 6. A post hoc binomial analysis reported 78.6% and 95.2%, the same percentages reported in the product label.
What varies
- Indication: prostate cancer, endometriosis, preoperative anemia, and central precocious puberty have different treatment goals.
- Formulation: the labeled route and release interval are specific to the named product and strength.
- Monitoring: the product labels describe different hormone, clinical, and bone-health checks for different settings.
Research
Research evidence
Leuprolide has clinical study and label evidence across several distinct conditions. The prostate cancer comparison measured testosterone suppression; the pediatric dose-ranging study measured stimulated LH, growth, and pubertal development.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Leuprolide versus degarelix | 610 treated patients with prostate cancer at various stages | Randomized, open-label, 12-month phase 3 trial | Monthly intramuscular leuprolide versus subcutaneous degarelix | The estimated rate of testosterone suppression at or below 50 ng/dL from day 28 through day 364 was 96.4% with leuprolide and 97.2% with the degarelix 240/80 mg schedule. | The endpoint was biochemical, the study was open-label, and patients had different disease stages. It does not establish a survival advantage. | Strong for the measured hormone endpoint |
| Three-month depot in central precocious puberty | 84 children with central precocious puberty | Randomized, open-label, six-month phase 3 dose-ranging study | Intramuscular 11.25 mg or 30 mg depot every three months | The prespecified life-table analysis estimated peak-stimulated LH below 4 mIU/mL from months 2 through 6 at 78.4% and 95.2% for the respective dose groups. Assessments were at months 2, 3, and 6. | The study followed children for six months and enrolled both previously treated and untreated patients. A post hoc binomial analysis reported 78.6% and 95.2%, the same percentages reported in the product label. | Strong for the studied short-term endpoint |
| Lupron Depot 3.75 mg clinical label | Patients with endometriosis or selected preoperative fibroid-related anemia | US prescribing information and clinical study summaries | Monthly intramuscular depot | The label describes endometriosis management and, with iron, preoperative hematologic improvement in a defined fibroid-related anemia setting. | For fibroid-related anemia, the label specifies iron therapy and a preoperative course of up to three months. The endometriosis indication has different treatment limits. | Product-specific clinical evidence |
Cautions
Safety and unknowns
- The prostate-cancer label warns that an initial testosterone rise can worsen symptoms, including bone pain, urinary obstruction, or spinal cord compression. New or worsening symptoms require prompt clinical attention.
- The endometriosis label limits treatment because of bone-density loss, some of which may persist after treatment. Norethindrone add-back can reduce that loss in the labeled endometriosis setting, but has its own contraindications and precautions.
- The 3.75 mg gynecologic label warns that depression can occur or worsen, especially in patients with a history of depression. It advises monitoring and appropriate referral for new or worsening depression. The product is contraindicated in patients with undiagnosed abnormal uterine bleeding.
- The prostate-cancer label describes metabolic changes, cardiovascular concerns, QT interval effects, and convulsions. Product-specific precautions should be reviewed with the clinician.
- The pediatric label describes emotional or behavioral changes, seizures, and reports of increased pressure around the brain. Headache or vision changes should be reported to the treating clinician.
- Severe allergic and serious skin reactions are reported in leuprolide labels. The gynecologic and pediatric products are contraindicated during pregnancy; the relevant product label also describes fetal-harm and fertility concerns. The 3.75 mg gynecologic label cautions that suppression of ovulation does not ensure contraception.
Product quality
Product identity and quality
Approved depot products use different delivery systems and release periods. A product name and milligram amount alone do not establish the same route, interval, or indication.
Product and indication
The prostate-cancer, pediatric, and gynecologic labels specify different uses and formulations.
Route and release period
Lupron Depot is intramuscular and Eligard is subcutaneous; each has formulation-specific administration instructions.
Mechanism
How it is proposed to work
Leuprolide first activates the GnRH receptor. Continued exposure reduces the pituitary hormone signals that normally drive testosterone or estrogen production.
The initial stimulation can raise LH, FSH, and sex hormones before suppression. In prostate cancer, a temporary rise in testosterone may worsen existing symptoms.
Degarelix is a GnRH receptor antagonist, not an agonist. The two drugs have different initial hormone responses despite both being used for androgen deprivation.
FAQ
Common questions
Why can a GnRH agonist lower sex hormones?
It first stimulates the pituitary, but continued exposure suppresses gonadotropin release and downstream sex hormones.
Are all leuprolide products interchangeable?
No. Products have different indications, release characteristics, routes, strengths, and schedules. The relevant label must be checked.
Details
Technical details
Sources
References
- 1.
DailyMed. Lupron Depot prescribing information for advanced prostate cancer
Intramuscular depot formulations, prostate cancer indication, initial flare, and safety warnings.
- 2.
DailyMed. Lupron Depot 3.75 mg prescribing information
Endometriosis and preoperative fibroid-related anemia indications, dosing limits, and bone-density precautions.
- 3.
DailyMed. Lupron Depot-Ped prescribing information
Central precocious puberty indication, pediatric depot schedules, monitoring, and warnings.
- 4.
DailyMed. Eligard prescribing information
Subcutaneous leuprolide depot formulation for advanced prostate cancer.
- 5.
PubMed. Three-month leuprolide depot in central precocious puberty: a randomized trial
doi:10.1210/jc.2011-2704 PMID:22344198 NCT00635817
A six-month, open-label comparison of two pediatric depot doses and stimulated LH suppression.
- 6.
PubMed. Degarelix versus leuprolide in prostate cancer: a randomized phase 3 trial
doi:10.1111/j.1464-410X.2008.08183.x PMID:19035858 NCT00295750
A 12-month comparison of testosterone suppression with monthly leuprolide and degarelix.